Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10371884" target="_blank" >RIV/00216208:11140/17:10371884 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/17:10371884

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.12113" target="_blank" >http://dx.doi.org/10.21873/anticanres.12113</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12113" target="_blank" >10.21873/anticanres.12113</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature

Popis výsledku v původním jazyce

Background/Aim: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite the fact that it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients. Materials and Methods: Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio (HR) according to the method of Peto. Results: Analysis was performed on 19 studies including 5,998 patients. A 47.3% of patients received postoperative chemotherapy and included 52.8% males and 47.2% females. Eight studies included some rectal cancer patients although this cohort was not clearly defined in 3 of these. MSI observed in 20.8% (mean) of patients (median 19.9%). HR for overall survival (OS) of MSI vs. microsatellite stable (MSS) tumors for the entire population: 0.73 (95% confidence interval (CI) = 0.331.65); HR for disease-free survival (DFS): 0.60 (95% CI = 0.271.32). No statistical significant difference was found when studies analyzing MSI with genotyping (MG) and immuno histochemistry (IHC) were compared separately (MG vs. IHC: HR OS 0.45, 95% CI = 0.10-2.05 vs. 0.95, 95% CI = 0.57-1.58; HR DFS 0.51, 95% CI = 0.14-1.85 vs. 0.67, 95% CI = 0.26-1.70). However, numerically MSI determination with genotyping shows significantly lower hazard ratios for both DFS and OS. Separate analysis of studies describing colon cancer patients only showed HR OS 0.72 (95% CI = 0.31-1.71); HR DFS 0.60 (95% CI = 0.27-1.31). Conclusion: No significant relation was found between MSI status and OS or DFS. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended. New large scale high quality studies are needed to answer this question definitively, since currently analyzed studies vary considerably.

Název v anglickém jazyce

Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature

Popis výsledku anglicky

Background/Aim: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite the fact that it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients. Materials and Methods: Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio (HR) according to the method of Peto. Results: Analysis was performed on 19 studies including 5,998 patients. A 47.3% of patients received postoperative chemotherapy and included 52.8% males and 47.2% females. Eight studies included some rectal cancer patients although this cohort was not clearly defined in 3 of these. MSI observed in 20.8% (mean) of patients (median 19.9%). HR for overall survival (OS) of MSI vs. microsatellite stable (MSS) tumors for the entire population: 0.73 (95% confidence interval (CI) = 0.331.65); HR for disease-free survival (DFS): 0.60 (95% CI = 0.271.32). No statistical significant difference was found when studies analyzing MSI with genotyping (MG) and immuno histochemistry (IHC) were compared separately (MG vs. IHC: HR OS 0.45, 95% CI = 0.10-2.05 vs. 0.95, 95% CI = 0.57-1.58; HR DFS 0.51, 95% CI = 0.14-1.85 vs. 0.67, 95% CI = 0.26-1.70). However, numerically MSI determination with genotyping shows significantly lower hazard ratios for both DFS and OS. Separate analysis of studies describing colon cancer patients only showed HR OS 0.72 (95% CI = 0.31-1.71); HR DFS 0.60 (95% CI = 0.27-1.31). Conclusion: No significant relation was found between MSI status and OS or DFS. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended. New large scale high quality studies are needed to answer this question definitively, since currently analyzed studies vary considerably.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

12

Strana od-do

6563-6574

Kód UT WoS článku

000417022100008

EID výsledku v databázi Scopus

2-s2.0-85038129708